Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Toshifumi Akizawa"'
Autor:
Yusuke Hatakawa, Rina Nakamura, Toshifumi Akizawa, Motomi Konishi, Akira Matsuda, Tomoyuki Oe, Motoaki Saito, Fumiaki Ito
Publikováno v:
Biomolecules, Vol 14, Iss 5, p 586 (2024)
Despite the extensive research conducted on Alzheimer’s disease (AD) over the years, no effective drug for AD treatment has been found. Therefore, the development of new drugs for the treatment of AD is of the utmost importance. We recently reporte
Externí odkaz:
https://doaj.org/article/3dc6c8224bc8487d9553531a7e0cd4bb
Publikováno v:
Alzheimer’s Research & Therapy, Vol 15, Iss 1, Pp 1-9 (2023)
Abstract Background The development of drugs for Alzheimer’s disease (AD), which is related to the misfolding and aggregation of amyloid-β (Aβ), is high in demand due to the growing number of AD patients. In this study, we screened 22 kinds of 5-
Externí odkaz:
https://doaj.org/article/66e048a3ea2a424cae14b80f14f3bc3b
Publikováno v:
Biomolecules, Vol 12, Iss 12, p 1766 (2022)
We recently discovered JAL-TA9 (YKGSGFRMI), a short hydrolytic peptide that we termed a Catalytide. The catalytic center of JAL-TA9 was modeled using MM2 and MMFF94 parameters and identified as GSGFR. Additionally, a structure–activity relationship
Externí odkaz:
https://doaj.org/article/c1787e3a01e042e5902c3b76f131ba80
Autor:
Yusuke Hatakawa, Rina Nakamura, Motomi Konishi, Toshiyasu Sakane, Akiko Tanaka, Akira Matsuda, Motoaki Saito, Toshifumi Akizawa
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 7, Iss 1, Pp n/a-n/a (2021)
Abstract Introduction We recently discovered a short synthetic peptide derived from the ANA/BTG3 protein Box A region called ANA‐TA9 (SKGQAYRMI), which possesses catalytic activity. Herein we demonstrated the proteolytic activity of ANA‐TA9 again
Externí odkaz:
https://doaj.org/article/1a4ef79e0bc543bfad0b980ef972f1af
Autor:
Yusuke Hatakawa, Akiko Tanaka, Tomoyuki Furubayashi, Rina Nakamura, Motomi Konishi, Toshifumi Akizawa, Toshiyasu Sakane
Publikováno v:
Pharmaceutics, Vol 13, Iss 10, p 1673 (2021)
We have recently reported Catalytides (Catalytic peptides) JAL-TA9 (YKGSGFRMI) and ANA-TA9 (SKGQAYRMI), which are the first Catalytides found to cleave Aβ42. Although the Catalytides must be delivered to the brain parenchyma to treat Alzheimer’s d
Externí odkaz:
https://doaj.org/article/b82be5b1e02e41e7b28e8ec0bbeb9e0b
Autor:
Yusuke Hatakawa, Rina Nakamura, Motomi Konishi, Toshiyasu Sakane, Motoaki Saito, Toshifumi Akizawa
Publikováno v:
Heliyon, Vol 5, Iss 9, Pp e02454- (2019)
We have recently reported about shorter proteolytic peptides termed Catalytide as general name. JAL-TA9 (YKGSGFRMI), a fragment peptide derived from Box A region of Tob1 protein, is the first Catalytide and cleaves Aβ42 and its fragment peptides.Her
Externí odkaz:
https://doaj.org/article/ea5ff82952114542b2acc0a8e645bd4a
Publikováno v:
Biomolecules, Vol 4, Iss 2, Pp 510-526 (2014)
Prions are the cause of neurodegenerative disease in humans and other mammals. The structural conversion of the prion protein (PrP) from a normal cellular protein (PrPC) to a protease-resistant isoform (PrPSc) is thought to relate to Cu2+ binding to
Externí odkaz:
https://doaj.org/article/0f20675679d04c759edcceedeaeee7e6
Publikováno v:
International Journal of Cell Biology, Vol 2012 (2012)
Cells are usually surrounded by the extracellular matrix (ECM), and adhesion of the cells to the ECM is a key step in their migration through tissues. Integrins are important receptors for the ECM and form structures called focal adhesions (FAs). For
Externí odkaz:
https://doaj.org/article/ae1b482b30d74bfbb097da15480ee861
Background The development of drugs for Alzheimer’s disease (AD), which is related to the misfolding and aggregation of Amyloid-β (Aβ), is high in demand due to the growing number of AD patients. In this study, we screened 22 kinds of 5-mer synth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9aa7046aaf6b3bc50a1b0f7623a5bc05
https://doi.org/10.21203/rs.3.rs-2255031/v1
https://doi.org/10.21203/rs.3.rs-2255031/v1
Autor:
Motomi Konishi, Yusuke Hatakawa, Rina Nakamura, Toshiyasu Sakane, Tomoyuki Furubayashi, Toshifumi Akizawa, Akiko Tanaka
Publikováno v:
Pharmaceutics
Volume 13
Issue 10
Pharmaceutics, Vol 13, Iss 1673, p 1673 (2021)
Volume 13
Issue 10
Pharmaceutics, Vol 13, Iss 1673, p 1673 (2021)
We have recently reported Catalytides (Catalytic peptides) JAL-TA9 (YKGSGFRMI) and ANA-TA9 (SKGQAYRMI), which are the first Catalytides found to cleave Aβ42. Although the Catalytides must be delivered to the brain parenchyma to treat Alzheimer’s d